Statement on 15th Anniversary of Medicines for Malaria Venture (MMV)
by Ray Chambers
UN Special Envoy and MMV Board Chair Congratulates Medicines for Malaria Venture on 15 Years of Service
Today I extend congratulations and appreciation to Medicines for Malaria Venture (MMV) on celebrating 15 years of excellence.
MMV was conceived as a foundation in 1999, and it has flourished since then as a public-private partnership focused on reducing the burden of malaria in disease-endemic countries by facilitating the delivery of new, effective and affordable antimalarial drugs. This includes work on finding a drug that can be administered in a single dose and will cure the disease but, more importantly, prevent transmission. When such drugs enter the market we will surely be on a faster path to eliminating malaria from the world.
MMV has a long and notable track record of conceptualizing and implementing innovative partnerships — bridging relationships between academia, funders, non-governmental organizations, private sector and pharmaceutical giants, –to push forward advances in malaria treatment.
We applaud their continued commitment to saving lives. It is through MMV’s commitment, and that of others, that we continue to make great progress towards achievement of the Millennium Development Goals and ridding the world of an ancient disease.